Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-03-31
2010-11-16
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C514S001000
Reexamination Certificate
active
07833513
ABSTRACT:
This invention relates to methods for diagnosing Alzheimer's Disease (AD) by determining the level or function of insulin, insulin-like growth factors, their receptors and/or their downstream signaling molecules. The invention further relates to methods for the treatment of AD by administering an insulin agonist and an insulin-like growth factor agonist. The invention additionally provides an animal model of AD and methods of screening for agents useful in the treatment, amelioration, or prevention of AD.
REFERENCES:
patent: 5817623 (1998-10-01), Ishii
patent: 6787552 (2004-09-01), Sakuma et al.
patent: 7119104 (2006-10-01), Sakuma et al.
patent: 7402597 (2008-07-01), Sakuma et al.
patent: 2004/0058873 (2004-03-01), Esmond et al.
patent: 2004/0060077 (2004-03-01), Esmond et al.
patent: 2005/0043242 (2005-02-01), Esmond et al.
patent: 2005/0137122 (2005-06-01), Sharif
patent: WO 03/062405 (2003-07-01), None
patent: WO 03/077940 (2003-09-01), None
patent: WO 2004/060871 (2004-07-01), None
patent: WO/2004/093910 (2004-11-01), None
Lackey et al. Growth Hormone and IGF Research, 10: 1-13, Feb. 2000.
Stewart and Liolitsa, Diabetic Medicine, 16: 93-112, Feb. 1999.
Merriam-Webster's Online Dictionary (2003) Retrieved from: http://www.m-w.com Retrieved on Nov. 5, 2007.
Vickers JC. Drugs Aginig 19(7):487-494, 2002.
Kojo et al., J Pharmacol Sci, 93:347-355, Nov. 2003.
Dokmeci D., Folia Medica, 46(2): 5-10 (2004).
de la Monte et al., J Alzheimer's Res., 10(1):89-109, 2006.
Abraham, R., et al., “Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease,”Hum. Genet. 109:646-652, Springer-Verlag Berlin (2001).
“Activation of Receptor Boosts Development of Precancerous Intestinal Polyps,”ASBMB Today:17, American Society for Biochemistry and Molecular Biology (Mar. 2004).
Adelman, A.M. and Daly, M.P., “Initial Evaluation of the Patient with Suspected Dementia,”Am. Fam. Physician 71:1745-1750, American Academy of Family Physicians (May 2005).
Ait-Ghezala, G., et al., “Confirmation of association between D10S583 and Alzheimer's disease in a case-control sample,”Neurosci. Lett. 325:87-90, Elsevier Science Ltd. (2002).
Alessi, D.R. and Downes, C.P., “The role of PI 3-kinase in insulin action,”Biochim. Biophys. Acta 1436:151-164, Elsevier Science B.V. (1998).
Balasubramanian, A.S., “Amyloid Beta Peptide Processing, Insulin Degrading Enzyme, and Butyrylcholinesterase,”Neurochem. Res.26:453-456, Kluwer Academic/Plenum Publishers (2001).
Bassaganya-Riera, J., et al., “Peroxisome Proliferator-Activated Receptors: The Nutritionally Controlled Molecular Networks that Integrate Inflammation, Immunity and Metabolism,”Curr. Nutr. Food Sci. 1:179-187, Bentham Science Publishers Ltd. (Jun. 2005).
Bedu, E., et al., “Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases,”Expert Opin. Ther. Targets 9:861-873, Ashley Publications Ltd. (Aug. 2005).
Berger, J. and Wagner, J.A., “Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors,”Diabetes Technol. Ther. 4:163-174, Mary Ann Liebert, Inc. (2002).
Bernstein, H.-G., et al., “Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques,”Neurosci. Lett. 263:161-164, Elsevier Science Ireland Ltd. (1999).
Bertram, L., et al., Evidence for Genetic Linkage of Alzheimer's Disease to Chromosome 10q,Science 290:2302-2303, American Association for the Advancement of Science (2000).
Blass, J.P., et al., “The role of the metabolic lesion in Alzheimer's disease,”J. Alzheimers Dis. 4:225-232, IOS Press (2002).
Blum-Degen, D., et al., “Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders?,”J. Neural Transm. 46:139-147, Springer-Verlag (1995).
Boussaha, M., et al., “Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease,”Neurosci. Lett. 329:121-123, Elsevier Science Ireland Ltd. (2002).
Braak, H. and Braak, E., “Neuropathological stageing of Alzheimer-related changes,”Acta Neuropathol. 82:239-259, Springer-Verlag (1991).
Brun, R.P., et al., “Peroxisome proliferator-activated receptor gamma and the control of adipogenesis,”Curr. Opin. Lipidol. 8:212-218, Rapid Science Publishers (1997).
Bucht, G., et al., “Changes in Blood Glucose and Insulin Secretion in Patients with Senile Dementia of Alzheimer Type,”Acta Med. Scand. 213:387-392, Elsevier Science Inc. (1983).
Burgering, B.M. and Coffer, P.J., “Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction,”Nature 376:599-602, Macmillan Magazines Ltd. (1995).
Carantoni, M., et al., “Alzheimer Disease and Vascular Dementia: Relationships with Fasting Glucose and Insulin Levels,”Dement. Geriatr. Cogn. Disord. 11:176-180, Karger (2000).
Carson, M.J., et al., “Insulin-like Growth Factor I Increases Brain Growth and Central Nervous System Myelination in Transgenic Mice,”Neuron 10:729-740, Cell Press (1993).
Castellani, R.J., et al., “Active Glycation in Neurofibrillary Pathology of Alzheimer Disease: Nε-(Carboxymethyl) Lysine and Hexitol-Lysine,”Free Radic. Biol. Med. 31:175-180, Elsevier Science Inc. (2001).
Chakrabarti, R. and Rajagopalan, R., “The Role of PPARs in Obesity and other Insulin Resistance Associated Disorders,”Curr. Med. Chem.—Immun., Endoc.&Metab. Agents 4:67-73, Bentham Science Publishers Ltd. (Jun. 2004).
Chawla, A., et al., “PPARδ is a very low-density lipoprotein sensor in macrophages,”Proc. Natl. Acad. Sci. USA 100:1268-1273, National Academy of Sciences (Feb. 2003).
Cockrell, J.R. and Folstein, M.F., “Mini-Mental State Examination (MMSE),”Psychopharmacol. Bull. 24:689-692, MedWorks Media (1988).
Combs, C.K., et al., “Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists,”J. Neurosci. 20:558-567, Society for Neuroscience (2000).
Condorelli, F., et al., “Caspase Cleavage Enhances the Apoptosis-Inducing Effects of BAD,”Mol. Cell. Biol. 21:3025-3036, American Society for Microbiology (2001).
Connor, B., et al., “Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus,”Brain Res. Mol. Brain Res. 49:283-290, Elsevier Science B.V. (1997).
Cook, D.G., et al., “Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-ε4 Allele,”Am. J. Pathol. 162:313-319, American Society for Investigative Pathology (Jan. 2003).
Craft, S., et al., “Effects of Hyperglycemia on Memory and Hormone Levels in Dementia of the Alzheimer Type: A Longitudinal Study,”Behav. Neurosci. 107:926-940, American Psychological Association (1993).
Craft, S., et al., “Memory Improvement Following Induced Hyperinsulinemia in Alzheimer's Disease,”Neurobiol. Aging 17:123-130, Elsevier Science Inc. (1996).
Craft, S., et al., “Insulin Metabolism in Alzheimer's Disease Differs According to Apolipoprotein E Genotype and Gender,”Neuroendocrinology 70:146-152, Karger (1999).
Craft, S., et al., “Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose,”Arch. Gen. Psychiatry 56:1135-1140, American Medical Association (1999).
Craft, S., et al., “Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype,”Psychoneuroendocrinology 28:809-822, Pergamon Press (Aug. 2003).
Craft, S., et al., “Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship
de la Monte Suzanne Marie
Wands Jack Raymond
Beattie Ingrid A.
Kolker Daniel E.
MacFarlane Stacey
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Rhode Island Hospital
LandOfFree
Treatment of Alzheimer's Disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of Alzheimer's Disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Alzheimer's Disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252384